Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Reversible tumorigenesis by MYC in hematopoietic lineages.

The targeted repair of mutant protooncogenes or the inactivation of their gene products may be a specific and effective therapy for human neoplasia. To examine this possibility, we have used the tetracycline regulatory system to generate transgenic mice that conditionally express the MYC protooncogene in hematopoietic cells. Sustained expression of the MYC transgene culminated in the formation of malignant T cell lymphomas and acute myleoid leukemias. The subsequent inactivation of the transgene caused regression of established tumors. Tumor regression was associated with rapid proliferative arrest, differentiation and apoptosis of tumor cells, and resumption of normal host hematopoiesis. We conclude that even though tumorigenesis is a multistep process, remediation of a single genetic lesion may be sufficient to reverse malignancy.

Pubmed ID: 10488335


  • Felsher DW
  • Bishop JM


Molecular cell

Publication Data

August 12, 1999

Associated Grants

  • Agency: NCI NIH HHS, Id: CA 44338
  • Agency: NCI NIH HHS, Id: K08 CA75967-01

Mesh Terms

  • Animals
  • Apoptosis
  • Cell Survival
  • Cell Transformation, Neoplastic
  • Doxycycline
  • Genes, myc
  • Hematologic Neoplasms
  • Hematopoietic Stem Cells
  • Humans
  • In Situ Nick-End Labeling
  • Mice
  • Mice, Transgenic
  • Restriction Mapping
  • Thymus Neoplasms
  • Tumor Cells, Cultured